Last edition
News about Clinical Trials
Marvel Biosciences Reports Positive Preclinical Results for MB-204 in Fragile X Syndrome Study
Marvel Biosciences has reported positive preclinical results for its lead drug candidate, MB-204, in a Fragile X syndrome study conducted with the FRAXA Research Foundation. The findings further support the therapy's potential to treat autism spectrum disorder and related neurodevelopmental conditions.
Clinical Trials | 06/08/2026 | By News Bureau
Innovent Doses First Patient in Pivotal IBI363/TAK-928 CRC Study
Innovent has dosed the first patient in its pivotal IBI363/TAK-928 study, advancing next-generation immunotherapy for colorectal cancer.
Clinical Trials | 06/08/2026 | By News Bureau
4Moving Biotech has completed patient enrollment in its global Phase 2a INFLAM MOTION trial, assessing the safety and efficacy of investigational therapy 4P004 for inflammatory knee osteoarthritis.
Clinical Trials | 05/08/2026 | By News Bureau
Otsuka's Voyxact Meets Key Phase 3 Endpoint in IgA Nephropathy Study
Otsuka presented new Phase 3 VISIONARY trial findings showing that Voyxact significantly slowed kidney function decline over two years, reinforcing its potential as a disease-modifying therapy for adults with primary IgA nephropathy.
Clinical Trials | 05/08/2026 | By News Bureau
AusperBio Doses First Patient in HBV Candidate AHB-171 Study
AusperBio has dosed the first patient in the AHB-171 clinical study, advancing its HBV pipeline and proprietary Au-HALO liver-targeting delivery technology siRNA platform.
Clinical Trials | 03/08/2026 | By News Bureau
Novo Nordisk Provides Phase 3 ZEUS Trial Update
Novo Nordisk shared an update on the phase 3 ZEUS trial evaluating patients with ASCVD, CKD and inflammation enrolled in a placebo-controlled study.
Clinical Trials | 03/08/2026 | By News Bureau
GlycoNex Doses First Patient in Phase 1 Trial of GNX1021
GlycoNex dosed the first patient in its phase 1 trial of GNX1021, advancing its glycan-directed Antibody Drug Conjugate (ADC) while exploring global licensing and co-development deals.
Clinical Trials | 03/08/2026 | By News Bureau
Moleculin Reports Encouraging Interim Phase 2/3 Data for Annamycin in Relapsed or Refractory AML
Moleculin Biotech has reported encouraging preliminary blinded data from its pivotal Phase 2/3 MIRACLE trial, with Annamycin plus cytarabine achieving a 37 percent composite complete remission rate in relapsed or refractory acute myeloid leukaemia.
Clinical Trials | 03/08/2026 | By News Bureau
Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo
Pfizer's phase 3 studies showed LITFULO significantly improved facial and total repigmentation in patients with nonsegmental vitiligo versus placebo.
Clinical Trials | 31/07/2026 | By News Bureau
Hansoh Pharma Reports Positive Phase 3 Results for Ris-Rez in China
Hansoh Pharma reported positive phase 3 results for Ris-Rez in China, while GSK advances development across lung cancer, prostate cancer and other solid tumors.
Clinical Trials | 31/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy